Latest Updates on Experimental Vaccines Against Pancreatic Cancer
A new horizon of hope emerges in the treatment of one of the deadliest cancers. In recent months, and with very recent news from August 2025, research on a vaccine for pancreatic cancer has shown unprecedented advances, generating great optimism in the medical community and among patients.
It is essential to clarify that, for now, these are experimental therapeutic vaccines, meaning they do not prevent the initial development of cancer but are designed to treat it, primarily by preventing the disease from reappearing after surgery. Although they are not yet a standard treatment available to the general public, the results from clinical trials are highly promising.
Currently, two main types of vaccines are leading the research:
1. “Universal” or Off-the-Shelf Vaccines
This is one of the most recent and exciting areas of progress. These vaccines target genetic mutations that are common in the vast majority of pancreatic tumors.
- Latest Advance (August 2025): Phase 1 clinical trials of a vaccine called ELI-002 2P have shown very positive results. This vaccine trains the immune system to recognize and attack cancer cells carrying mutations in the KRAS gene, present in approximately 90% of pancreatic cancers.
- Key Results: In a study involving 25 patients with pancreatic and colorectal cancer, 68% developed a strong immune response. This group experienced a significantly longer period without cancer recurrence and greater overall survival compared to those who did not respond as strongly.
- Main Advantage: Since it is not personalized, its production is simpler, faster, and more cost-effective, which could facilitate broader access in the future if trials continue to succeed.
2. Personalized mRNA Vaccines
This strategy, driven by the same mRNA (messenger RNA) technology used for COVID-19 vaccines, creates a customized treatment for each patient.
- How It Works: After a patient undergoes surgery to remove a pancreatic tumor, the tumor is genetically analyzed to identify its unique mutations, called neoantigens. A personalized mRNA vaccine is created containing instructions for the patient’s own immune cells (specifically T lymphocytes) to recognize and destroy any remaining cancer cells in the body.
- Clinical Trial Results: In a groundbreaking trial led by Memorial Sloan Kettering Cancer Center in collaboration with BioNTech, approximately half of the patients who received the personalized vaccine after surgery showed a strong immune response. In these patients, the vaccine significantly delayed cancer recurrence compared to those who did not have an immune response.
- Main Advantage: Its highly personalized nature allows for a very specific attack against an individual’s cancer.
How Do These Vaccines Work?
The fundamental principle is immunotherapy. Pancreatic cancer is notoriously skilled at “hiding” from the immune system. These vaccines act as intensive “training” for the body’s T lymphocytes, teaching them to identify specific proteins on cancer cells as a threat and to attack them selectively and effectively, no matter where they are in the body.
Current Status and Future Outlook
As of August 2025, these vaccines are in clinical trial phases (Phase 1 and advancing toward Phase 2). Researchers describe the results as a “paradigm shift” and “real hope.”
The next crucial step is conducting larger clinical trials (Phase 2 and 3) to confirm safety and efficacy in a greater number of patients. If these studies continue to yield positive results, these vaccines could become a standard part of pancreatic cancer treatment in the coming years.
While widespread availability is not yet a reality, current advances represent the most significant progress in decades against this disease and offer tangible hope for drastically improving survival and quality of life for future patients.
